Dr. Joel Potash, MD Family Medicine Medicare: Medicare Enrolled Practice Location: 249 Route 11a, Nedron, NY 13120 Phone: 315-469-6449 Fax: 315-469-0593 |
News Archive
ARYx Therapeutics, Inc. today announced that the US Food and Drug Administration has informed the Company of an additional delay in providing needed guidance on the Phase 3 development of ARYx's product candidate for the treatment of various gastrointestinal disorders, naronapride. In this latest communication with ARYx, the FDA suggests a response will not be forthcoming until July 2011 at the earliest.
Activating a mother's immune system during her pregnancy disrupts the development of neural cells in the brain of her offspring and damages the cells' ability to transmit signals and communicate with one another, researchers with the UC Davis Center for Neuroscience and Department of Neurology have found.
ZEISS has brought fiscal year 2012/13 to a successful conclusion (reporting date: 30 September 2013) with a new record high in revenue. The company generated revenue totaling EUR 4.190 billion (prior year: EUR 4.163 billion) and earnings (EBIT) of EUR 335 million (prior year: EUR 420 million).
Politico: "Reid moved swiftly to ensure that his home state of Nevada wouldn't be hurt by Medicaid changes included in the health care reform bill moving through the Senate Finance Committee. Now some of his Democratic colleagues are demanding the same treatment for their states."
› Verified 2 days ago